News

  • 20 October 2017

    Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the treatment of patients with Wilson Disease, will be presented tomorrow at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC.

  • 12 October 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.

  • 9 October 2017

    Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company presented pharmacokinetic data from a Phase 1 clinical trial in healthy volunteers and from a preclinical model of Staphylococcus aureus pneumonia for its investigational lead product candidate, ASN100, which is currently in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. These data were described in three poster presentations at IDWeek™ 2017, taking place in San Diego from October 4 – 8. 

  • 6 October 2017

    Wilson Therapeutics (publ.) today announced that data from a Phase 2 trial of WTX101 (bischoline tetrathiomolybdate), an investigational oral first-in-class copper-protein-binding agent for the treatment of patients with Wilson Disease, has been published online in The Lancet Gastroenterology & Hepatology and will be available in print in the December issue. The results show that treatment with WTX101 induces rapid copper control, significantly reducing free copper levels by 72% from baseline after approximately 3 months, and is associated with significant early improvements in neurological symptoms and disability. The study data have previously been reported at medical conferences but this is the first time the complete study results are available in a peer-reviewed scientific journal.

  • 4 October 2017

    Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company has appointed William “Chip” Clark and David McGirr to its Board of Directors and promoted Michael Gray to Chief Operating Officer and Chief Financial Officer.